IconOVir Bio Revenue and Competitors
Estimated Revenue & Valuation
- IconOVir Bio's estimated annual revenue is currently $1.9M per year.
- IconOVir Bio's estimated revenue per employee is $77,500
- IconOVir Bio's total funding is $77M.
Employee Data
- IconOVir Bio has 24 Employees.
- IconOVir Bio grew their employee count by -47% last year.
IconOVir Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Business Operations | Reveal Email/Phone |
2 | Controller & Treasurer | Reveal Email/Phone |
3 | Head Legal | Reveal Email/Phone |
4 | Chief Technology Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Senior Director | Reveal Email/Phone |
7 | Chief Scientific Officer | Reveal Email/Phone |
8 | Chief Technology Officer | Reveal Email/Phone |
9 | Clinical Development Operations Leader | Reveal Email/Phone |
10 | Scientist, Translational Research | Reveal Email/Phone |
IconOVir Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is IconOVir Bio?
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O'Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.
keywords:N/A
$77M
Total Funding
24
Number of Employees
$1.9M
Revenue (est)
-47%
Employee Growth %
N/A
Valuation
N/A
Accelerator
IconOVir Bio News
SAN DIEGO--(BUSINESS WIRE)-- IconOVir Bio, Inc. (IconOVir), ... our SAB bring a deep understanding of oncolytic viruses and cancer biology,...
IconOVir Bio, Inc., a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced it has raised $77 million in a Series A financing. The financing was co-led by Nextech and Vida Ventures, with ...
Series A financing co-led by Nextech and Vida Ventures with participation from Two River Group, Bellco Capital, Polaris Partners, GV, Wellington Partners and Logos Capital IconOVir formed by team behind Kite Pharma, Allogene Therapeutics and Kronos Bio Proprietary oncolytic virus platform base ...
When Gilead Sciences snapped up Forty Seven last year, CEO Mark McCamish could have called it a day. He joined a few boards and thought about retiring, but he's jumped back into the game because he felt a calling to contribute to the treatment of cancer. Now, as CEO of IconOVir Bio, he’s shepher ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $182.7M | 24 | 4% | N/A |
#2 | $2.4M | 24 | N/A | N/A |
#3 | $2.4M | 24 | N/A | N/A |
#4 | $3.9M | 24 | -8% | $1.2M |
#5 | $5.6M | 24 | -11% | N/A |